32 Klaus Stoeckel et al., “Stability of Cephalosporin Prodrug Esters in Human Intestinal Juice: Implications for Oral Bioavailability”, Antimicrobial Agents and Chemotherapy 42 (1998), 2602–2606.
32
Antimicrobial Agents and Chemotherapy
33 W. Graninger, “Pivmecillinam – Therapy of Choice for Lower Urinary Tract Infection”, International Journal of Antimicrobial Agents 22 (2003), suppl. 2, 73–78; George Zhanel et al., “A Canadian National Surveillance Study of Urinary Tract Isolates from Outpatients: Comparison of the Activities of TrimethoprimSulfamethoxazole, Ampicillin, Mecillinam, Nitrofurantoin, and Ciprofloxacin”, Antimicrobial Agents and Chemotherapy 44 (2000), 1089–1092.
33
International Journal of Antimicrobial Agents
Antimicrobial Agents and Chemotherapy
34 A. Sullivan et al., “Effect of Perorally Administered Pivmecillinam on the Normal Oropharyngeal, Intestinal and Skin Microflora”, Journal of Chemotherapy (2001), 299–308; A. Heimdahl et al., “Effect of Bacampicillin on Human Mouth, Throat and Colon Microflora”, Infection 7 (1979), S446 – S451.
34
Journal of Chemotherapy
Infection
35 Carolos Amabile-Cuevas, Jack Heinemann, “Shooting the Messenger of Antibiotic Resistance: Plasmid Elimination as a Potential CounterEvolutionary Tactic”, Drug Discover Today 9 (2004), 465–467.
35
Drug Discover
36 Johna DeNap, Paul Hergenrother, “Bacterial Death Comes Full Circle: Targeting Plasmid Replication in Drug-Resistant Bacteria”, Organic Biomolecular Chemistry 3 (2005), 959–966.
36
Organic Biomolecular Chemistry
37 Johna DeNap et al., “Combating Drug-Resistant Bacteria: Small Molecule Mimics of Plasmid Incompatibility as Antiplasmid Compounds”, Journal of the American Chemical Society 126 (2004), 15402-15404.
37
Journal of the American Chemical Society